Switzerland’s Windward Bio Group AG, which develops long-acting therapies for asthma and other inflammatory diseases, plans to raise about $174.9 million in an IPO. The company is offering roughly 10.3 million shares at $16–18 and expects to begin trading on Nasdaq on November 13 under the ticker WWB. At the same time, France’s Sanofi intends to invest an additional $50 million in the company through a private placement.

At a price of $17 per share, Windward’s market capitalization after the IPO and the concurrent placement would be about $986.6 million. The lead underwriters are Jefferies, TD Cowen, Piper Sandler, and UBS Investment Bank.
Betting on less frequent dosing
Windward Bio is developing antibodies to treat severe respiratory and skin diseases, including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. The company aims to reduce injection frequency compared with existing treatments.
Its lead candidate, WIN378, targets TSLP, a protein involved in triggering inflammatory responses. The already approved drug Tezspire is directed at the same target. However, Windward is developing WIN378 for dosing twice a year, whereas Tezspire is administered every four weeks.
Less frequent injections could make treatment more convenient for patients. But WIN378 remains an experimental drug: its efficacy and safety still need to be confirmed in further trials.
Next readouts expected in 2027
WIN378 is being evaluated in the Phase 2/3 POLARIS-1 study in severe uncontrolled asthma. In September, Windward reported positive interim Phase 2 results: the company observed improved lung function and reduced inflammatory markers. Based on these data, it selected dose levels and initiated Phase 3.
The next major Phase 2 results are expected in the first half of 2027. Windward plans to receive the Phase 3 POLARIS-1 results in the first half of 2029. Enrollment in the second Phase 3 study, POLARIS-2, is expected to begin in the first half of 2027.
Separately, WIN378 is being studied in COPD in the Phase 2 SIRIUS trial. Results are expected in the second half of 2027.
Second candidate targets two pathways
Another Windward program is WIN027, a bispecific antibody. It simultaneously targets TSLP and IL-13, two proteins involved in inflammatory processes. The company believes this approach could deliver a more pronounced and longer-lasting effect, though this still needs to be validated.
WIN027 is in a Phase 1 trial in healthy volunteers. Full results from this stage are expected in the first half of 2027. Enrollment for studies in COPD and atopic dermatitis is also planned for the same period.
Sanofi to invest an additional $50 million
In addition to the IPO, Windward agreed to a private placement for Sanofi. The pharmaceutical company will purchase shares and prepaid warrants totaling $50 million. This transaction is expected to close concurrently with the IPO.
As a result, if priced at the midpoint of the range, Windward could raise about $225 million before underwriting commissions and expenses. The company estimates net proceeds from the two transactions at approximately $203.8 million.
Previously, Windward raised $310 million in equity financing. Its investors include Novo Holdings, OrbiMed, Blue Owl, and RTW Investments.
The company is not yet generating product revenue
Windward is in the clinical development stage and does not yet have any products approved for commercial sale. For the first half of 2026, its net loss totaled $42.6 million, compared with $22.8 million a year earlier.
The proceeds from the IPO and the private placement, together with existing resources, will be used primarily to fund trials of WIN378 and WIN027. Windward estimates the financing will last into the first half of 2029. This outlook depends on trial timelines and actual spending.
For investors, the key catalysts will be clinical-trial results. Positive early-stage data do not guarantee success in later studies or approval for sale. Development delays and rising costs may also require additional financing.
Not an individual investment recommendation.